CME ACADEMIC PROGRAM & FACULTY
CME Series 1: CASE-BASED MULTIDISCIPLINARY MANAGEMENT OF GENITOURINARY MALIGNANCIES
CME Series 2: CHALLENGES IN WOMEN'S SEXUAL MEDICINE
Education Program 2019
Our Mission: Bringing together the top academic physicians and thought leaders in the world with practicing community clinicians to create an environment for high-level interaction in order to obtain up-to-date medical knowledge to benefit patients. Learning is patient-centered and case-based to maximize the translation of medical knowledge to clinical practice.
We are offering two medical education series for 2019:
Series 1: CASE-BASED MULTIDISCIPLINARY MANAGEMENT OF GENITOURINARY MALIGNANCIES: INTEGRATING NEW DATA, IMMUNOTHERAPY AND PRECISION MEDICINE WITH FUTURE DIRECTIONS
Focus on: Surgery, pathology, radiology, internal medicine, medical oncology, radiation oncology and urology
Series 2: CHALLENGES IN WOMEN'S SEXUAL MEDICINE:In-depth, Comprehensive Care for Women’s Sexual Health Across the Lifespan
Focus on: Issues of teen, LGBTQ, vulvar pain, menopause, cancer, and more
Accreditation:
CME Credit:
Each educational session is approved for a maximum of 16.5 AMA PRA Category 1 credits by the Institute for Medical and Nursing Education Inc. See full accreditation and credit designation information below.
Because this is a dedicated medical education conference, course participants will have unprecedented access to faculty to interact with them with inquiries both during and after the program. The detailed program will be supplied to participants closer to departure date.
Your all-inclusive CME conference will include ½ day education program followed ½ day tour program at our ports of call
Faculty Series 1 - Genitourinary
“CASE-BASED MULTIDISCIPLINARY MANAGEMENT OF GENITOURINARY MALIGNANCIES: INTEGRATING NEW DATA, IMMUNOTHERAPY AND PRECISION MEDICINE WITH FUTURE DIRECTIONS”
Evan Yu, MD – Course Director
Professor of Medicine, University of Washington School of Medicine
Medical Director, Clinical Research Support, Fred Hutchinson Cancer Research Center
Member, Fred Hutchinson Cancer Research Center
Evan Y. Yu, M.D., is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research. He graduated Alpha Omega Alpha from the University of Washington School of Medicine. He completed internal medicine residency at the Brigham and Women’s Hospital and oncology fellowship and post-doctoral training at the Dana-Farber Cancer Institute. He returned to Seattle at the end of 2004 to join the faculty at the University of Washington and Fred Hutchinson Cancer Research Center. He now is a Full Professor, the Clinical Research Director for GU malignancies, Core Director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium at his institution. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. In addition to an active clinical and research practice, he also is the Medical Director for Clinical Research Support at the Fred Hutch/University of Washington Cancer Consortium. He served as a Hematology/Oncology Fellowship Program Director for a decade at the Fred Hutchinson Cancer Research Center. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is newly appointed as the Co-Chair for the National Cancer Institute Prostate Cancer Task Force. He remains active in SWOG and he also serves as an editor for Clinical Cancer Research, Clinical Genitourinary Cancer, and Uro-Today.
Ravi A. Madan, MD – Course Director
Prostate Cancer Expert
Bethesda, MD
Dr. Madan is a medical oncologist and has worked at a leading research institution to develop new therapies for prostate cancer for more than a decade. He is interested immunotherapy strategies in prostate cancer. Dr. Madan also believes that immunotherapy combinations could have more clinical success in prostate cancer in the future.
Areas of Expertise
immunotherapy, prostate cancer, therapeutic cancer vaccines, immune check point inhibitors, metastatic prostate cancer, medullary thyroid cancer
Richard Lee, MD, PhD
Assistant Professor of Medicine, Harvard Medical School, Boston, MA
Assistant Physician, Massachusetts General Hospital Cancer Center, Boston, MA
Dr. Lee is an academic medical oncologist specializing in genitourinary malignancies. He earned A.B. and A.M. degrees in chemistry from Harvard University, and M.D. and Ph.D. (molecular biology) from the Albert Einstein College of Medicine. He completed residency training in Internal Medicine at Massachusetts General Hospital (MGH) and fellowship training at the combined Dana-Farber Cancer Institute-MGH hematology / oncology program, with post-doctoral research at the Whitehead Institute of MIT. He is an Assistant Professor of Medicine at Harvard Medical School and practices medical oncology at the MGH Cancer Center.
Dr. Lee is the vice-chair of the NCCN Prostate Cancer Treatment Guidelines. He has diverse research interests. His main interest is the development of biomarkers of treatment response, primarily with circulating tumor cells (CTCs) in prostate cancer patients. He is also involved in clinical trials, including phase I/II trials for prostate, bladder, and kidney cancers. His research has led to significant grant funding from the Department of Defense Prostate Cancer Research Program, the Prostate Cancer Foundation, and Stand Up 2 Cancer.
Edwin M Posadas, MD FACP KM
Co-Director, Translational & Clinical Oncology Research Program
Medical Director, Urologic Oncology Program
Samuel Oschin Comprehensive Cancer Institute
Clinical Chief, Division of Hematology Oncology
Associate Professor, Department of Medicine
Cedars-Sinai Medical Center
Clinical Associate Professor
Department of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Edwin M. Posadas, MD, FACP, KM is director of the Translational Oncology Program and the medical director of the Urologic Oncology Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. He is also the clinical chief of the Division of Hematology/Oncology at the Department of Medicine at Cedars-Sinai Medical Center. He has both clinical and research interests in the treatment of advanced prostate cancer and the biology of cancer metastasis. Dr. Posadas is studying the mechanisms through which cancer cells in localized tumors spread to other parts of the body. A protein called FYN, a member of a cancer-causing gene family, was identified in his laboratory as a possible regulator of metastasis and the neuroendocrine phenotype of prostate cancer. Additionally, his laboratory has been studying the role of circulating tumor cells (CTCs) and immune cells (ICs) as biomarkers in prostate and other cancers using novel nanotechnology platforms. His current research interests focus on the most aggressive subtypes of prostate cancer that spread to organs such as the liver and lungs. Dr. Posadas is working to define the function of FYN, CTCs, and ICs in prostate cancer, with the goal of applying his basic science findings to the development of new therapies and diagnostic tools that will directly benefit men with advanced prostate cancer. Clinically, he specializes in the use of medical therapies for prostate, kidney, bladder, and testis cancer with an emphasis on integrated, trans-disciplinary care. Dr. Posadas completed his undergraduate medical studies at the Johns Hopkins University School of Medicine followed by an internal medicine residency at the University of Michigan and medical oncology fellowship at the National Cancer Institute. His research lab is funded by the National Cancer Institute’s Alliance for Nanotechnology in Cancer Program, the Department of Defense Prostate Cancer Research Program, and the Prostate Cancer Foundation.
Tanya Dorff, MD
Associate Clinical Professor
Head of Genitourinary Cancer Program
Department of Medical Oncology & Therapeutics Research
City of Hope
Following a residency at Mt. Sinai Hospital in New York City, Dr. Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr. Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr. Dorff serves as associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology and serves on the NCCN guidelines panel for prostate cancer as well as the NCI Prostate Cancer Task Force. She has lectured on prostate and bladder cancer treatment nationally and internationally, and has presented her research at national meetings. Current research interests include immunotherapy for prostate cancer and the effects of fasting on chemotherapy side effects and cancer control. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.
John Gore, MD, MS, FACS
Associate Professor, Department of Urology, University of Washington
John L. Gore, MD, MS, FACS is a urologic oncologist and health services researcher. Dr. Gore received his MD from Baylor College of Medicine following which he completed his urology training at UCLA. He then received his health services research training as a Robert Wood Johnson Clinical Scholar at UCLA. Dr. Gore is currently an Associate Professor in Urology, Adjunct Associate Professor in Surgery at the University of Washington, and Affiliate Investigator at the Fred Hutchinson Cancer Research Center in Seattle, WA. He is pursuing a translational health services and patient-centered outcomes research program toward improving access to care, quality of life, and quality of care for urologic cancers.
Petros Grivas, MD, PhD
Associate Professor, Department of Medicine, Division of Oncology
Clinical Director, Genitourinary Cancers Program University of Washington
Associate Member, Clinical Research Division Fred Hutchinson Cancer Research Center
Dr. Petros Grivas is a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. He is the Clinical Director of the Genitourinary Cancers Program at University of Washington and Associate Professor in the Dept of Medicine, Division of Oncology.
Dr. Grivas completed his training at the University of Patras Medical School and took his M.D. degree in 2005; he then pursued Ph.D. in Medical Oncology under the mentorship of key academic faculty and defended his thesis successfully in late 2008. He completed his Residency in Internal Medicine at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia, USA) in 2010. He then completed his Fellowship in Hematology/Oncology at University of Michigan (Ann Arbor, USA) in 2013. He stayed there as Clinical Lecturer for another year before he was recruited as Assistant Professor at the Cleveland Clinic (Cleveland, USA), where he was leading the bladder/urothelial cancer program, pursuing clinical and translational research, teaching trainees, and seeing patients with GU cancers.
He has had main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer, and is considered a key opinion, thought leader and international expert, giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research. He is dedicated to efficient, personalized and outstanding patient care and believes in optimal patient-physician relationship as well as community outreach.
Faculty Series 2
“ Challenges In Women's Sexual Medicine”
Karen E. Adams MD, FACOG, NCMP – Course Director
Professor of Obstetrics and Gynecology
Vice Chair for Education
Director, OHSU Center for Women’s Health Menopause and Sexual Medicine Program
Oregon Health and Science University
Dr. Adams is a Professor of Obstetrics and Gynecology at Oregon Health and Science University (OHSU), where she is Director of the OHSU Center for Women’s Health Menopause and Sexual Medicine Program. She has been the OHSU OBGYN Residency Director for fourteen years and Vice Chair for Education for ten. She is a North American Menopause Society Certified Menopause Practitioner and is a nationally recognized expert in medical education. She has served as a member of the Associate of Professors of Gynecology and Obstetrics Board of Directors, and is a member of the Accreditation Council on Graduate Medical Education OBGYN Residency Review Committee, an appointed board that accredits all 241 OBGYN residency programs and 85 OBGYN fellowship programs across the country. She co-directs the ACOG School for New OBGYN Residency Program Directors, and she is a member of the ACGME Wellness Working Group, a national group of medical educators working to decrease burnout among medical students, residents, and practicing physicians. She has served as an oral board examiner for the American Board of OBGYN since 2008.
Dr. Adams is founder and director of the Menopause and Sexual Medicine Program in the OHSU Center for Women’s Health. This program brings together specialists in many fields to provide comprehensive health care for women in perimenopause and beyond, with a special focus on midlife sexuality. She is a North American Menopause Society Certified Menopause Practitioner and is a Fellow of the International Society for the Study of Women’s Sexual Health. She has published more than 30 scientific articles, given hundreds of lectures nationally and internationally, and loves growing older and wiser along with her patients!
Geri D. Hewitt, MD
Section Chief, Obstetrics and Gynecology, Nationwide Children’s Hospital, Columbus, Ohio
Professor of Clinical Obstetrics in the Departments of Obstetrics and Gynecology and Pediatrics at The Ohio State University College of Medicine
Geri D. Hewitt, MD, is Chief of the Section of Obstetrics and Gynecology at Nationwide Children's Hospital and a Professor of Clinical Obstetrics in the Departments of Obstetrics and Gynecology and Pediatrics at The Ohio State University College of Medicine. Dr. Hewitt's primary interests are caring for the gynecologic and reproductive health needs for young girls as well as adolescents. Dr. Hewitt is an examiner for the American Board of Obstetrics and Gynecology. Dr. Hewitt is a Fellow of the American College of Obstetricians and Gynecologists and a co-editor for the Journal of Pediatric and Adolescent Gynecology's Tips for Clinicians section.
Catherine LeClair, MD
Professor of Obstetrics and Gynecology,
Director, OHSU Center for Women’s Health Program in Vulvar Health
Oregon Health and Sciences University
Dr. Leclair practices general obstetrics and gynecology with a special focus in vulvar health and sexuality. Dr. Leclair is currently only accepting new patients for the program in vulvar health.
As a specialist in vulvovaginal health, Dr. Leclair’s research is concentrated around the complex relationship of these conditions and their impact on quality of life and sexual intimacy. Her research efforts also include vulvar pain, sexuality, vulvar skin diseases and vaginitis.
After completing medical school at the University of Vermont, Dr. Leclair returned to the Pacific Northwest for her training and medical career. She chose OHSU for its reputation of clinical excellence, academics and collegial atmosphere of the department. Dr. Leclair has a young family and enjoys outdoor activities including hiking, running, cross-country skiing, biking, and gardening.
Mindy Goldman, MD
Professor of Gynecology and Gynecologic Surgery
Director, gynecology Center for Cancer Survivors and At-Risk Women
University of California San Francisco
Dr. Goldman specializes in women's health care and gynecology issues for cancer patients and those at risk for cancer. She is the Director of the Gynecology Center for Cancer Survivors and At-Risk Women which is jointly sponsored by UCSF's Carol Franc Buck Breast Care Center and the National Center of Excellence in Women's Health. She is a member of the Helen Diller Comprehensive Cancer Center and works closely with cancer specialists to help ease the gynecologic side effects of cancer treatment.
Her clinical expertise focuses on fertility options, safety of pregnancy, side effects of breast cancer hormonal therapies (like tamoxifen and aromatase inhibitors), management options for chemotherapy or treatment induced menopause, vaginal dryness/sexual dysfunction and surgeries to remove ovaries when indicated. She sees women with other cancer types focusing on similar survivorship issues as well as women with hereditary cancer syndromes, focusing on screening and prevention strategies. She also sees general gynecology patients and provides both office based care and gynecologic surgery when indicated.
Nicole Cirino, MD
Associate Professor of Psychiatry and Obstetrics and Gynecology
Director, OHSU Center for Women’s Health Division of Women’s Mental Health and Wellness
Oregon Health and Science University
Dr. Cirino was trained as a reproductive psychiatrist and has specialty experience working with mental health and sexual health issues experienced exclusively by women across their reproductive life cycle. Dr. Cirino has worked extensively with women and their families who experience perinatal mood and anxiety symptoms since 2003. She also treats women experiencing mood and anxiety symptoms related to genital pain, infertility, menopause, gynecologic oncology, and sexual health. She can provide psychiatric assessment, second opinion services, medication management and psychotherapy.
Jennifer Potter, MD
Professor of Internal Medicine
Director, LGBT Population Health Program, The Fenway Institute
Harvard Medical School
Director of LGBT Population Health and Co-Chair of The Fenway Institute, Dr. Jennifer Potter has extensive clinical, medical education, research, and mentoring experience. She has designed and implemented numerous curricula for health professionals, focused on LGBT health, women’s health, sexual health, cancer survivorship, and care for people with disabilities. In addition, she co-edited two seminal textbooks on LGBT health (The Fenway Guide to LGBT Healthand Trauma, Resilience and Health Promotion in LGBT Patients; What Every Healthcare Provider Should Know), and co-authored an American Association of Medical Colleges’ monograph entitled Implementing Curricular and Institutional Climate Changes to Improve Health Care for Individuals Who are LGBT, Gender Nonconforming, or Born with DSD: A Resource for Medical Educators. Previously co-director of a Behavioral Health Curriculum for medical residents at Beth Israel Deaconess Medical Center and Site Director for a HRSA-funded Primary Care HIV Track at Fenway Health, Dr. Potter currently serves nationally as the Co-Chair of the AAMC AXIS Committee and Associate Editor of the LGBT Collection for MedEdPORTAL. Dr. Potter is a Professor of Medicine at Harvard Medical School (HMS), where she has been a longstanding member of the CME Committee and serves as the Advisory Dean and Director of the William B. Castle Society, director of an online Harvard Global Academy course on LGBT health, and associate director of the HMS Continuing Medical Education (CME) course Primary Care Internal Medicine. She herself presents regularly at undergraduate, graduate, and CME venues across the country and serves as a consultant to domestic and international medical schools engaged in LGBT curricular inclusion efforts.
CME AGENDA
Education Program 2019
Your all-inclusive CME conference will include ½ day education program followed ½ day tour program at our ports of call
Title of Educational Activity:
Series 1: Case-based Multidisciplinary Management of Genitourinary Malignancies: Integrating New Data, Immunotherapy and Precision Medicine with Future Directions
Intended Audience:
This conference is intended for physicians in the specialties of oncology, urology, radiology, general surgeons.
Learning Objectives:
At the conclusion of this educational activity participants will be able to:
-
Understand the nuances to management of the many different disease states of prostate cancer, spanning localized disease through metastatic castration-resistant prostate cancer.
-
Understand the data surrounding efficacy, side effects and earlier use of novel androgen pathway targeting agents and chemotherapy for men with prostate cancer.
-
Understand future directions of investigation in prostate cancer, specifically for patients with DNA repair alterations and identification of patient populations likely to have promising results with newer immune-oncology agents.
-
Understand the nuances to management of the different disease states of urothelial cancer, spanning non-muscle invasive bladder cancer to metastatic disease.
-
Understand the role of chemotherapy and immune-oncology agents in the neoadjuvant, adjuvant and metastatic urothelial carcinoma settings.
-
Understand future directions of investigation in urothelial cancer with combination therapies and novel targeted agents.
-
Understand newer surgical considerations for renal cell carcinoma, especially new data with cytoreductive nephrectomy.
-
Understand the utilization of antiangiogenic agents and novel targeted therapies for renal cell carcinoma in the adjuvant and metastatic settings.
-
Understand the role of immune-oncology agents for renal cell carcinoma.
-
Understand how to incorporate next generation sequencing and precision medicine into everyday practice.
-
Understand the spectrum of testicular germ cell tumor disease states, prognosis, and therapeutic management.
-
Understand the staging and treatment of penile cancer.
-
Recognize rare variant genitourinary cancers and how to appropriately manage them.
CME Accreditation and Credit Designation Statement:
The Institute for Medical and Nursing Education, Inc. (IMNE), is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
IMNE designates this live activity for 16.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DAILY CME PROGRAM AGENDA - SERIES 1
November 12, 2019: Prostate Cancer
Case Presentation
Screening and Surveillance
Biochemical recurrence, next generation imaging and treatment
Metastatic hormone-sensitive prostate cancer
November 13, 2019: Prostate Cancer continued
MO CRPC treatment and Sequencing agents
DNA Repair considerations in prostate cancer
Immuno-oncology considerations
Case Presentations
November 14, 2019: Bladder Cancer
Non-muscle invasive bladder cancer, muscle invasive bladder cancer and surgical considerations
Bladder conservation
Neoadjuvant vs. adjuvant chemotherapy and trials
Case Presentations
November 15, 2019: Bladder and Kidney Cancer
Metastatic bladder cancer including chemotherapy, IO and combination trials
New agents for metastatic bladder cancer
Surgical considerations for kidney cancer, including new data against cytoreduction
Case Presentations
November 16, 2019: Kidney Cancer
Adjuvant therapy for kidney cancer
Metastatic kidney cancer and drug sequencing
Immunotherapies for kidney cancer
Novel agents and utilization of next generation sequencing for kidney cancer
Case Presentations
November 17, 2019: Rare GU Cancers
Neuroendocrine prostate cancer and investigation into the future
Variant bladder cancers
Variant kidney cancers
Penile cancer
Testicular cancer/germ cell tumors
Title of Educational Activity:
Series 2: Challenges in Women’s Sexual Medicine: In-depth, Comprehensive Care for Women’s Sexual Health Across the Life Span
Intended Audience: This conference is intended for physicians in the specialties of obstetrics/gynecologist, gynecology oncology, pediatricians, family medicine/primary care
Learning Objectives:
At the conclusion of this educational activity participants will be able to:
-
Obtain a thorough and accurate sexual history
-
Screen for hypoactive sexual desire disorder (HSDD) and initiate treatment
-
Provide appropriate care for sexually active teens that includes pregnancy prevention and risk reduction
-
Diagnose and initiate treatment for painful sex and other common sexual problems in women in the teen years, reproductive years, and menopausal years
-
Recognize and treat vulvar and vaginal conditions that can lead to sexual dysfunction
-
Initiate treatment for common menopausal symptoms
-
Discuss common sexual health concerns facing women with cancer and various approaches to treatment
-
Perform evidence-based breast cancer screening and initiate risk-reduction strategies
-
Communicate with sex- and gender-minority people in a way that minimizes barriers they experience in health care systems
-
Utilize principles of trauma-informed care in all clinical encounters.
CME Accreditation and Credit Designation Statement:
The Institute for Medical and Nursing Education, Inc. (IMNE), is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
IMNE designates this live activity for 16.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DAILY CME PROGRAM AGENDA - SERIES 2
November 12, 2019: Teen Sexual Issues
Geri Hewitt (Ohio State, Natl Children’s Hospital)
Teen sexuality: what clinicians need to know
Pregnancy prevention in adolescents
When Sex Hurts Part One: Pelvic pain, endometriosis, and ovarian cysts
November 13, 2019: Vulvar and Vaginitis
Catherine Leclair (OHSU)
When Sex Hurts Part Two: Vestibulodynia, vulvodynia, and vaginismus
Recognizing and Treating Vulvar Dermatoses
The Challenge of Vaginal Discharge
November 14, 2019: Menopause
Karen Adams (OHSU)
Taking a Sexual History
Menopause Management in 2019: relieving symptoms and promoting health
When Sex Hurts Part Three: genitourinary syndrome of menopause
November 15, 2019: Alternatives to Hormone Therapy
Mindy Goldman (UCSF)
Alternatives to Hormone Therapy for Menopausal Symptoms
Sexuality in Cancer Survivors
Update 2019: Breast cancer Screening and Prevention
November 16, 2019: Sexual Therapy and Dysfunction
Nicole Cirino (OHSU)
Utilizing an Office Based Approach to Low Libido in Women
Sex Therapy Techniques for Female Sexual Dysfunction
Neurobiology of Sexual Function Across the Female Reproductive Cycle
November 17, 2019: LGBTQI
Jennifer Potter (Harvard)
Understanding and Communicating With Sex and Gender-Minority People: a clinical approach
Minority Stress and Health Equity: how identity and experience shape health outcomes
The Approach to the Patient: utilizing principles of trauma-informed care